CN100479815C - Medicine for treating M2 type acute myelogenous leukemia and preparation method of injection thereof - Google Patents
Medicine for treating M2 type acute myelogenous leukemia and preparation method of injection thereof Download PDFInfo
- Publication number
- CN100479815C CN100479815C CNB2004100168901A CN200410016890A CN100479815C CN 100479815 C CN100479815 C CN 100479815C CN B2004100168901 A CNB2004100168901 A CN B2004100168901A CN 200410016890 A CN200410016890 A CN 200410016890A CN 100479815 C CN100479815 C CN 100479815C
- Authority
- CN
- China
- Prior art keywords
- rubescensine
- injection
- aml
- treating
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a medicine for treating M2 acute myeloid leukemia, in particular the Chinese medicine abstraction that inducing apoptosis for treating M2 acute myeloid leukemia and the injection prepared from this abstraction. It is characterized in that the rubescensine A can induce apoptosis of Kasumi-1 and AML, M2 primary leukomic cell, and prolong the life time of AML, M2 ascites carcinoma mouse. And the character of rubescensine an injection is dissolving the rubescensine an into dissolvent of propanediol, and/or tuwen 80, and/or alcohol to be diluted by normal saline, phosphate buffer or water for injection, and the concentration of dissolvent is reduced under 5-1 %. These injections dose non-toxicity reaction to Kunming mouse in 30-50 mg/kg, therefore can be used in clinical application.
Description
Technical field
The present invention is a kind of medicine of the M2 of treatment type acute myeloid leukaemia and the preparation method of injection thereof.
Background technology
Acute leukemia is that unusual hematopoietic stem disease takes place for a kind of genome, and is often relevant with the sudden change of chromosome translocation, inversion, disappearance and proto-oncogene etc.Minimum leukemia patient over half is with different chromosome translocations, but the formed fusion rotein leukemogenesis of transposition cell malignant proliferation, differentiation are obstructed, apoptosis is suppressed, and these are different with tumor such as solid tumor.The leukemia clinical onset is dangerous, poor prognosis, and its treatment is still based on chemotherapy.In recent years advocate induce the differentiation with apoptosis-induced therapy be that the prognosis that improves the leukaemic has brought hope, for example all-trans-retinoic acid (ATRA), Harbin Medical University of Shanghai hematology institute exploitation at first report and illustrate arsenic trioxide (ATO) the treatment M3 type acute myeloid leukaemia (AML M3) of its mechanism of action by Shanghai hematology's institute, for leukemic differentiation and the apoptosis therapy of inducing provides example.But ATRA, ATO are not good to other tumor efficiencies such as solid tumors, may be different with the pathogenesis of leukemic pathogenesis and solid tumor relevant, point out simultaneously and should choose different Therapeutic Method according to its pathogenesis, can obtain good efficacy different types of tumors.
Leukemia has the branch of acute and chronic, and acute person divides acute lymphoblastic leukemia (ALL) and acute myeloid leukaemia (AML), and the latter divides M1~M7 several hypotypes again.The leukemia of different subtype respectively has characteristics, and is also different to the reaction of treatment.M2 type acute myeloid leukaemia (AML M2) sickness rate is higher, accounts for 25% of all acute myeloid leukaemias, to have t (8; 21) chromosome translocation is a feature, symptom and signs such as heating, anemia, hemorrhage and granulocyte sarcoma are arranged clinically, and leukocyte increases in the peripheral blood, erythrocyte, thrombocytopenia.The treatment of AML M2 is based on chemotherapy such as cytosine arabinoside, daunorubicins, and lacks as ATRA, ATO for effective differentiation the AML M3, apoptosis induction therapy, thereby many in the world scientific research personnel are carrying out deep research for this type of therapy of exploitation.We studies show that, rubescensine A is in external AML, ALL that suppresses each hypotype and chronic myelocytic leukemia (CML) leukaemia's propagation and induce the apoptosis of these cells, but particularly responsive to AML M2.Rubescensine A can suppress the propagation of AML M2 cell strain Kasumi-1 cell and AML patient M2 primary leukemia cell, and induces these apoptosis, and this effect is time, dose dependent.Rubescensine A can prolong the life cycle of AML M2 ascites tumor mice in vivo, but and the apoptosis of pathologic finding demonstration rubescensine A inducing leukemia cell, thereby show that rubescensine A has therapeutical effect to AML M2, potential clinical value is arranged.But the poorly water-soluble of rubescensine A, oral absorption is few, has seriously limited its clinical practice, thereby we have prepared the rubescensine A injection, overcomes the few shortcoming of oral absorption with the method by intravenously administrable.
Summary of the invention
The objective of the invention is to develop a kind of medicine of the M2 of treatment type acute myeloid leukaemia, especially realize treatment M2 type acute myeloid leukaemia by cell death inducing.
Feature of the present invention, the one, adopt rubescensine A to handle AML M2 cell, can induce each hypotype AML, ALL, CML apoptosis of leukemia though find rubescensine A, its apoptosis induction effect to AML M2 leukaemia is particularly remarkable; The 2nd, prepared the rubescensine A injection, method is, earlier rubescensine A is dissolved in the solvents such as propylene glycol, Tween 80, ethanol, reuse normal saline or phosphate buffer or water for injection dilution make solvent concentration be reduced to 5% to below 1%; Or be dissolved in earlier in the ethanol, add the dilution of an amount of propylene glycol/Tween 80 reuse normal saline or phosphate buffer or water for injection, make solvent concentration be reduced to 5% to below 1%.These injection can supply clinical selecting for use.
Compare prior art, the present invention has following technical characterstic:
1, though this medicine has the broad-spectrum leukemia resisting action, its effect that realizes treating M2 type acute myeloid leukaemia by cell death inducing is particularly evident.
2, chemotherapy is still the main Therapeutic Method of present AML M2, and toxic and side effects is bigger; And bone marrow transplantation has higher transplant related mortality on the one hand, and suitable on the other hand donor is few and transplant required expense height, and tangible limitation is arranged equally.The rubescensine A toxic and side effects is low and cheap, thereby can overcome these shortcomings.
3, overcome rubescensine A poorly water-soluble, shortcoming that oral absorption is few, help developing the clinical application of rubescensine A.
4, for the exploitation leukemia especially apoptosis induction therapy of AML M2 lays the foundation.
The specific embodiment
I, we handle the Kasumi-1 cell with rubescensine A (0.5~5 μ M concentration), find that but apoptotic body and DNA " trapezoidal " band appear in its inducing leukemia cell, the Phosphatidylserine tableization detects positive with the original position apoptosis of terminal deoxyribotide transferase mediation, inferior G1 peak appears in cell cycle, and this effect is dosage-time dependence.Rubescensine A also can cause the disintegrate of Kasumi-1 cell mitochondrial transmembrane potential, the activation of caspases, the degraded of bcl-2 cancer protein etc.To other leukemia cell line such as NB4, HL-60, cells such as K562, U937, rubescensine A also can be induced its apoptosis, but desired concn is higher, between 5~15 μ M.
II, we separate primary leukemia cell from AML patient M2 of recurrence, refractory, handle the back with rubescensine A and find that rubescensine A can be induced these apoptosis of leukemia at 0.5~5 μ M; To the leukaemia in AMLM1, AML M3, AML M4, AML M5, CML and ALL source, rubescensine A needs higher concentration (2~15 μ M) can induce its apoptosis.
III, we go into the NOD/SCID mouse peritoneal with the Kasumi-1 injection cell and build up the ascites tumor model and with rubescensine A it is handled, find that rubescensine A is under the dosage condition of 7.5mg/ (kgd), 15mg/ (kgd), can prolong survival time of mice 32% and 44% respectively, the prompting rubescensine A comes in handy to the clinical treatment of AMLM2.
IV, a certain amount of 100% propylene glycol is joined purity is in 93%~99.9% the rubescensine A powder for we, stir repeatedly or blow and beat under the room temperature condition and make it abundant mixing, and leave standstill and rubescensine A was fully dissolved in 2~24 hours, then with normal saline/phosphate buffer dilution, solvent concentration is reduced to below 50%, 25%, 10%, 5% and 1%, form colourless, transparent clarifying rubescensine A solution, add an amount of hydrochloric acid or sodium hydroxide again and regulate pH value to 7.2, promptly form rubescensine A propylene glycol injection to 7.6.Rubescensine A can not precipitate and separate out in this injection.We also are dissolved in rubescensine A in the Tween 80 by above method, reuse normal saline/phosphate buffer dilution, solvent concentration is reduced to below 50%, 25%, 10%, 5% and 1%, form slightly yellow, transparent clarifying rubescensine A solution, add an amount of hydrochloric acid or sodium hydroxide again and regulate pH value to 7.2, form rubescensine A Tween 80 injection to 7.6.We also are dissolved in rubescensine A earlier in the propylene glycol, and the ratio in 1:1 to 10:1 adds Tween 80 then, and reuse normal saline/phosphate buffer dilution is made rubescensine A propylene glycol-Tween 80 injection by last method.In addition, we are dissolved in rubescensine A in the ethanol, make rubescensine A ethanol injection liquid and rubescensine A ethanol-propylene glycol injection by last method.V, we are injected into rubescensine A propylene glycol injection, rubescensine A Tween 80 injection, the agent of rubescensine A ethanol injection in the normal kunming mice body respectively, find that rubescensine A can not cause the death of mice under 30~50mg/kg condition.
Claims (1)
1, the application of rubescensine A in preparation treatment M2 type acute myeloid leukaemia medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100168901A CN100479815C (en) | 2004-03-11 | 2004-03-11 | Medicine for treating M2 type acute myelogenous leukemia and preparation method of injection thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100168901A CN100479815C (en) | 2004-03-11 | 2004-03-11 | Medicine for treating M2 type acute myelogenous leukemia and preparation method of injection thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1666738A CN1666738A (en) | 2005-09-14 |
CN100479815C true CN100479815C (en) | 2009-04-22 |
Family
ID=35038122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100168901A Expired - Fee Related CN100479815C (en) | 2004-03-11 | 2004-03-11 | Medicine for treating M2 type acute myelogenous leukemia and preparation method of injection thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100479815C (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100370981C (en) * | 2005-11-07 | 2008-02-27 | 上海第二医科大学附属瑞金医院 | Application of Maoeryisu for pharmacy |
CN1994293A (en) * | 2006-08-18 | 2007-07-11 | 上海交通大学医学院附属瑞金医院 | Application of oridonin in medicine preparation |
-
2004
- 2004-03-11 CN CNB2004100168901A patent/CN100479815C/en not_active Expired - Fee Related
Non-Patent Citations (6)
Title |
---|
R-干扰素联合冬凌草甲素对白血病U937细胞的增生抑制作用. 刘家军等.白血病.淋巴瘤,第12卷第6期. 2003 |
R-干扰素联合冬凌草甲素对白血病U937细胞的增生抑制作用. 刘家军等.白血病.淋巴瘤,第12卷第6期. 2003 * |
冬凌草甲素对HL-60细胞的生长抑制作用及其对细胞端粒酶活性的调节. 申家英等.白血病.淋巴瘤,第12卷第4期. 2003 |
冬凌草甲素对HL-60细胞的生长抑制作用及其对细胞端粒酶活性的调节. 申家英等.白血病.淋巴瘤,第12卷第4期. 2003 * |
冬凌草甲素的药学研究进展. 张典瑞等.中国药学杂志,第38卷第11期. 2003 |
冬凌草甲素的药学研究进展. 张典瑞等.中国药学杂志,第38卷第11期. 2003 * |
Also Published As
Publication number | Publication date |
---|---|
CN1666738A (en) | 2005-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Emerging platinum (IV) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment | |
CN102203063B (en) | Carbazole compounds and therapeutic uses of the compounds | |
Riordan et al. | Intravenous ascorbic acid: protocol for its application and use | |
Shao et al. | Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide | |
Von Holst et al. | Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas | |
CN102617610A (en) | Preparation method of porphyrin photosensitizer and anticarcinogen diad | |
JP2013231065A (en) | Use of ck 2 inhibitor for treatment and chemical sensitization of tumor unresponsive to anticancer agent | |
KR20160064726A (en) | Conjugate of Cell Penetrating Peptides-Anti-cancer Agent and Composition Comprising the Same | |
CN102552908A (en) | Pharmaceutical composition containing artemisinin, artemisinin derivatives and Bcl-2 inhibitor and application thereof | |
US6548541B1 (en) | Carboplatin analogs for cancer treatment | |
CN100479815C (en) | Medicine for treating M2 type acute myelogenous leukemia and preparation method of injection thereof | |
Zeng et al. | LYG-202, a new flavonoid with a piperazine substitution, shows antitumor effects in vivo and in vitro | |
CN105963244A (en) | Injection artesunate formulation and application thereof | |
CN104434939A (en) | Antitumor medicament composition of panax notoginseng saponins R7 and oridonin with capabilities of reducing toxicity and enhancing efficacy and application of antitumor medicament composition | |
CN103623394A (en) | Application of PEG-HM-3 and platinum, taxol or Emtriva medicines to preparation of solid tumor medicines | |
CN109730983A (en) | Application of the rhapontigenin in preparation treatment medication for treating pyemia | |
CN102993314A (en) | Anti-tumor fusion protein, as well as preparation method and application thereof | |
KR20140035974A (en) | Combined pharmaceutical compositions for the treatment of tumours | |
CN109045028A (en) | P53 transcription inhibitor PFT α HBr is preparing the application in anti-telomerase negative p53 positive tumor drug | |
CN1867573A (en) | Process for the preparation of trans- or cis-diammoniumdichlorodihydroxyplatinum(iv) salts and derivatives and their use for the preparation of pharmaceutical active agents | |
CN104146999A (en) | Oridonin and docetaxel toxicity reducing and efficacy enhancing antitumor drug composition and application thereof | |
CN103483187A (en) | 4-oxethyl-2-hydroxyl-6-methyl benzoic acid as well as medicinal composition and application thereof | |
US11833204B2 (en) | Visible light-activatable nanoparticles for cancer immunotherapy and use thereof | |
CN106668061B (en) | A kind of anticancer pharmaceutical composition containing cis-platinum | |
CN101797242A (en) | Application of cysteamine in preparing medicine for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090422 Termination date: 20100311 |